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Abstract
Interventions to improve the cognitive health of older adults are of critical importance. In the current study, we
conducted a double-blind, placebo-controlled clinical trial using a pill-based nutraceutical (NT-020) that
contained a proprietary formulation of blueberry, carnosine, green tea, vitamin D3, and Biovin to evaluate the
impact on changes in multiple domains of cognitive functioning. One hundred and five cognitively intact adults
aged 65–85 years of age (M= 73.6 years) were randomized to receive NT-020 (n= 52) or a placebo (n= 53).
Participants were tested with a battery of cognitive performance tests that were classified into six broad
domains—episodic memory, processing speed, verbal ability, working memory, executive functioning, and
complex speed at baseline and 2 months later. The results indicated that persons taking NT-020 improved
significantly on two measures of processing speed across the 2-month test period in contrast to persons on the
placebo whose performance did not change. None of the other cognitive ability measures were related to
intervention group. The results also indicated that the NT-020 was well tolerated by older adults, and the
presence of adverse events or symptoms did not differ between the NT-020 and placebo groups. Overall,
the results of the current study were promising and suggest the potential for interventions like these to improve
the cognitive health of older adults.
Introduction
Approximately 87% of the population of the UnitedStates will experience normal age-related cognitive
decline, as compared to the precipitous losses that are asso-
ciated with dementing disorders.1 In recent years, there has
been considerable interest in interventions to lessen normative
age-related declines in functioning, including those directed at
physical activity,2,3 gains through cognitive training efforts,4,5
as well as changes in the extent to which older adults are
cognitively stimulated throughout their lives.6,7 In addition,
there is considerable interest in the potential role of dietary
supplements and other therapeutics in the cognitive perfor-
mance of older adults.8 In the current study, we examine the
role of a pill-based nutraceutical on the cognitive performance
of older adults.
The basis for the use of polyphenol-rich nutritional sup-
plements as a moderator of age-related cognitive decline is
the age-related increase in oxidative stress9,10 and the po-
tential benefit of non-vitamin polyphenols, which are the
most abundant anti-oxidants in our diets. The benefits of
these substances for the cognitive health of older adults have
been reported in several studies.11 For example, Shukitt-
Hale’s recent review12 highlighted the potential benefits of
blueberries as a compound to impact age-related changes in
neuronal aging. Additionally, Devore and colleagues re-
cently reported that greater self-reported intakes of blue-
berries and strawberries were associated with slower rates of
cognitive decline.13 Although a number of lines of evidence
point toward the beneficial effects of these substances,
limitations of this research include the use of correlational
data as well as the lack of assessment of the bioavailability
of these polyphenolic compounds from diets.14
In the current study, we conducted a clinical trial using a
pill-based supplement or matched placebo control to evaluate
the impact on the cognitive performance of older adults. The
supplement (NT-020) is a proprietary formulation of blue-
berry, green tea extract (95% polyphenols), carnosine,
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VitaBlue (40% polyphenolics, 12.5% anthocyanins from
blueberries), and vitamin D3 (2000 IU per serving) and also
contains grape polyphenolics, including 5% resveratrol. In
experimental animal models of aging, there is good support
for a beneficial effect of polyphenolic components of fruits
and vegetables as well as teas (green and black) for im-
provements in cognition.15–17 For example, Bickford and
colleagues examined the impact of NT-020 on Morris water
maze performance among young animals (n= 10), as well as
older animals who received treatment of NT-020 (n= 13) or a
control diet (n= 13) for 3 weeks prior to behavioral testing.
The results showed that the NT-020 animals exhibited sig-
nificantly lower cumulative distances on the Morris water
maze test that is suggestive of better memory, as compared to
the older control animals. Furthermore, there was much less
variability among the treated old animals, as compared to the
control animals.
In the current study, we conducted a short-term (2
months) randomized clinical trial to examine the influence
of the nutraceutical NT-020 on the cognitive performance of
older adults. Participants were tested with a battery of
cognitive tasks at baseline and 2 months after being ran-
domized to the interventional supplement or placebo.
Methods
Participants
Participants for the current study were recruited from the
community using advertisements in local newspapers,
booths at health fairs and memory screening events, as well
as by postcards using commercially available mailing lists.
Inclusion criteria for the study were ages 65–85 years, na-
tive English speaking, able to understand and sign the in-
formed consent, and no evidence of dementia (Mini-Mental
State Examination [MMSE] scores ‡ 24). Exclusion criteria
for the study were history of known allergy to components
of the study supplements, use of high dose anti-oxidant
supplements other than what is provided in the trial, and
depressed mood as assessed by the Center for Epidemio-
logic Studies–Depression scale (scores greater than 5).
Measures
In addition to the measures of cognitive performance
described below, participants completed several descriptive
instruments at the screening assessment. These included a
questionnaire on basic demographic information, allergies,
and personal medical history. Global cognitive performance
was assessed using the MMSE18 cognitive screening tool.
Self-reported health status was evaluated using the SF-12
Health survey.19 Finally, depressive symptoms were as-
sessed using the 10-item Centers for Epidemiologic Studies
Depression Scale (CES-D).20
Cognitive measures
The battery of cognitive tests included standard measures
that were classified into six broad areas—episodic memory,
processing speed, verbal ability, working memory, execu-
tive functioning, and complex speed. Episodic memory, or
the ability to learn and remember a series of items, was
measured using the Auditory Verbal Learning Test
(AVLT),21 which involves reading and remembering a list
of 15 common English nouns. Two outcomes were exam-
ined here—immediate recall (average number of words re-
called across five learning trials) and delayed recall (number
of words recalled after a 20-min delay). Verbal ability was
total number correct on a recognition vocabulary test22 in
which participants had to identify a synonym of a target
word from one of five options. Processing speed provides an
index of how rapidly a person can respond and was mea-
sured using the Identical Pictures Test,22 the Number
Comparison task,22 and Trail Making A.23 For Trail Making
A, an inverse transformation was applied to scores before
standardization to account for this measure recording la-
tency, rather than number correct. Working memory pro-
vides an index of the ability to maintain some information in
memory while simultaneously manipulating other informa-
tion and was measured with the Forward and Backward
Digit Span task.24 Executive functioning includes skills that
are involved in the planning and execution of cognitive tasks
and was measured with Trail Making B,23 Category Flu-
ency,25 and Controlled Oral Word Association.26 For Trail
Making B, an inverse transformation was applied in the
same manner as Trail Making A. Finally, we assessed
complex speed, which assesses the ability to do multiple
mental tasks quickly using the number of correct items from
the Digit Symbol Test.24
Interventional compound and randomization schedule
The study was double blinded. Participants were ran-
domly assigned to receive NT-020 plus Biovin (900mg
proprietary formulation of blueberry, carnosine, green tea,
plus 200U vitamin D3, 40mg Biovin) or a matched placebo
control. Participants took one pill in the morning and one in
the evening. Participants were encouraged to take the pills
with food. Use of NT-020 and the placebo was covered by
an Investigational New Drug application (IND 104287)
from the Food and Drug Administration and the protocol
was registered on clinicaltrials.gov (NCT01963767). For the
randomization, the schedule was stratified on the basis of
age (65–74 years and 75–85 years) and participants were
randomized in blocks of ten.
Procedure
All procedures in the current study were approved by
Western Institutional Review Board (IRB), and all persons
who participated in the in-person assessments completed an
informed consent. The first contact for potential participants
was a telephone screen where basic inclusion and exclusion
criteria were assessed (e.g., aged 65–85 years). An in-person
screening visit was then scheduled within the next 2 weeks
during which the MMSE, CES-D, and SF-12 questionnaires
were assessed. Persons who passed the screening were
scheduled for a baseline visit during which participants were
randomized to receive NT-020 or a placebo, the cognitive
measures were administered, and participants received a
blood draw for safety markers (i.e., complete blood chem-
istry, comprehensive metabolic panel). In addition, partici-
pants received a 1-month supply of NT-020 or the placebo
together with a pill diary to record when the pills were taken
and any adverse events that occurred. One month later,
participants returned any unused NT-020 or placebo along
with the pill diary, received a blood draw, and received a
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new month’s supply of the supplement. One month later,
participants returned to repeat the cognitive assessment
battery and return any unused NT-020 or placebo, along
with the pill diary. In addition to the scheduled assessments
described above, participants were called 1 and 3 weeks
after the baseline and 1-month assessment to assess adverse
events and compliance with the supplement or placebo.
Statistical analyses
Considerations of sample size were based upon statistical
power analysis.27 Specifically, the study was originally pow-
ered to detect a medium-sized effect (d=0.5) with a total
sample size of 50 per group. The cognitive outcome analyses
were conducted using analysis of co-variance (ANCOVA)
values whereby scores from the final assessment point were
used as the outcomes and baseline scores were co-varied. For
randomized experiments with pre-test (baseline) and post-test
(follow-up) measurements, usually ANCOVA should be pre-
ferred with pre-test score as a co-variate. The reason for pre-
ferring ANCOVA over repeated-measures ANOVA is that the
latter has lower power and some assumptions (most promi-
nently homogeneity of variances) that are unlikely to be met.
Group status (NT-020, placebo) was the between-subjects
variable. A one-tailed p value of 0.05 was used for the analyses.
Results
Sample characteristics
Figure 1 displays the breakdown of the sample across the
longitudinal follow-up period. Of the 139 who participated
in the in-person screening session, 113 (81%) were ran-
domized to the NT-020 or the placebo groups. Across
the 2-month follow-up period, 2 persons dropped out of the
placebo group and 6 dropped from the NT-020 group. The
majority of persons who left the study indicated that they no
longer had time to participate. Calculation of the differences
in attrition between the groups using a Fisher exact test
revealed no significant differences ( p = 0.273). The demo-
graphic characteristics of the sample that completed the 2-
month follow-up are shown in Table 1. The sample was
approximately 73 years of age, almost two-thirds were
women, the majority of the sample was white, and the av-
erage MMSE score was over 29. A comparison of the two
groups using independent groups t-tests or chi-squared tests
revealed no statistically significant group differences.
Cognitive performance
Table 2 displays the means and standard errors for each of
the cognitive outcomes at baseline and follow-up. The results
of the ANCOVA indicated that group status was statistically
significant for Identical Pictures (F [1, 103]= 3.55, p= 0.03;
d= 0.37) and there was a trend toward significance for
Number Comparison (F [1, 103]= 2.43, p= 0.06; d= 0.31). In
both cases, the NT-020 group exhibited better performance
than the placebo group. None of the other group effects were
close to statistical significance ( p values> 0.10). To better
understand the effects on Identical Pictures and Number
comparison, we plotted the values in Fig. 2 and computed
within-groups paired t-tests on the scores from baseline and
follow-up. For Identical Pictures, the NT-020 group exhibited
statistically significant increases in performance (t [51]=
2.38, p= 0.021), whereas the placebo group remained stable
(t [52]= - 1.27, p= 0.211). Similarly, the NT-020 group ex-
hibited significant gains across the follow-up period on
Number Comparison (t [51]= - 2.62, p= 0.012), whereas the
placebo group experienced slight, but not statistically sig-
nificant, declines (t [52]= 0.51, p= 0.611).
Compliance and adverse events
Participants completed pill and symptom diaries across
the course of the follow-up period. Between the baseline and
the mid-point assessment, participants averaged 1.93 doses
per day out of a maximum of 2 and this did not vary as a
FIG. 1. Breakdown of the sample.
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function of intervention group (Mplacebo = 1.93, MNT-020 =
1.92; F [1, 103]= 0.06, p = 0.799). Between the mid-point
and the final measurement point, participants averaged 1.91
doses per day out of a maximum of 2 and this did not vary as
a function of intervention group (Mplacebo = 1.91, MNT-020 =
1.90; F [1, 103] = 0.24, p = 0.625). The most commonly re-
ported reasons for why participants missed a dose was that
they forgot or had an unrelated health issue (e.g., cold, fe-
ver) and decided not to take a dose that day.
Between baseline and the 1-month assessment point,
participants reported an average of four adverse events per
person across the follow-up period, but this did not differ
between intervention groups (Mplacebo = 4.38, MNT-
020 = 4.59; F [1, 103] = 0.03, p= 0.866). Similarly, the groups
did not differ in the number of adverse events between the
1-month and 2-month follow-up points (Mplacebo = 1.64,
MNT-020 = 1.86; F [1, 103] = 0.30, p= 0.584). The most
commonly reported symptoms were changes in activity
(e.g., lethargy, nervousness) or gastrointestinal symptoms
(e.g., upset stomach, diarrhea). One participant exhibited a
significant cardiac adverse event during the course of the
study during her first month of participation. This event was
reported to Western IRB and it was determined to be
unrelated to her participation in the study. The study was
unblinded for this participant and she was found to be in the
NT-020 arm. This participant was removed from the study.
Discussion
The results of the current study indicate modest im-
provements in two measures of processing speed after 2
months of taking NT-020, as compared to persons on the
placebo who showed no such improvement. None of the
other cognitive measures exhibited significant gains across
the follow-up period. The results of this randomized trial
indicate that cognitive performance can be improved by a
pill-based nutraceutical. The results of the current study are
noteworthy in that the domain of processing speed that was
improved here is most often affected early on in the course
of cognitive aging, and successful performance on these
tasks often underlies more complex cognitive outcomes,
such as memory and verbal ability.28
The small, but statistically significant, improvements in
processing speed observed here are consistent with other
nutraceutical interventions on cognitive performance. For
example, Krikorian and colleagues examined the consumption
of blueberry juice29 or Concord Grape juice30 on the cognitive
performance of older adults. They reported that participants
who consumed blueberry juice had better performance on
tests of memory as compared to their baseline performance, as
well as when compared to a matched group who consumed a
placebo beverage. Moreover, the magnitude of pre-test to
post-test improvements in the blueberry juice group was quite
substantial and amounted to an over 1 standard deviation
increase in performance. The results for Concord Grape juice,
which was tested using a randomized, placebo-controlled,
double-blind trial, were not as strong because it failed to
improve memory performance at the aggregate, although
there were improvements in distractibility.
Although the results of the current study were generally
consistent with those reported by Krikorian, there are a
number of differences between their work and the current
findings. First, no statistically significant effects on word
recall were observed because the results here indicated
improvements in processing speed only. Second, the effects
that were present here were somewhat smaller, amounting to
approximately 1/3 of a standard deviation of a difference.
There are a number of possible reasons for the differences in
the findings. First, the Krikorian studies used participants
who either exhibited ‘‘early memory changes’’29 or had
mild cognitive impairment.30 By contrast, the participants in
Table 1. Demographic Characteristics of the Sample
Placebo NT-020
(n = 53) (n= 52)
Years of age M 74.34 72.82
SD 5.48 5.54
Gender % Female 60.4 63.5
Race/ethnicity % White 100 92.3
Years of education M 15.61 15.88
SD 2.93 2.41
MMSE M 29.21 29.37
SD 1.03 1.07
CES-D M 2.75 2.85
SD 1.31 1.13
SF-12 M 29.89 29.38
SD 2.36 3.09
Table 2. Cognitive Test Scores (Mean – SE) from Baseline and Follow-Up for Placebo and NT-020 Groups
Placebo (n = 53) NT-020 (n= 52)
Measure Baseline Follow-up Baseline Follow-up
Identical Pictures 21.15 – .68 21.72 – .61 23.06– .68 24.12– .65
Number Comparison 21.85 – .63 21.60 – .65 21.35– .64 21.99– .65
Trailmaking A 40.91 – 1.52 39.09 – 1.70 37.58– 1.54 35.11– 1.72
Trailmaking B 92.98 – 6.05 84.60 – 4.95 84.80– 6.16 78.71– 5.04
Digit Span Forward 10.39 – .29 10.55 – .31 10.69– .29 10.57– .31
Digit Span Backward 6.39 – .33 7.11 – .34 7.82– .34 7.73 – .34
Category Fluency 15.39 – .64 16.13 – .61 17.21– .65 16.61– .62
COWA 38.98 – 1.64 41.07 – 1.49 40.84– 1.66 41.74– 1.51
Vocabulary 38.00 – .97 38.64 – 1.02 40.44– .97 40.71– 1.02
AVLT-Immediate 8.67 – .27 9.10 – .29 8.70– .27 9.23 – .29
AVLT-Delayed 8.51 – .44 8.73 – .48 8.13– .44 8.98 – .49
SE, standard error; COWA, Controlled Oral Word Association Test; AVLT, Auditory Verbal Learning Test.
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the current study were very high functioning, as evidenced
by the nearly perfect MMSE scores, as well as the high level
of educational attainment. It may be the case that because
the participants in the Krikorian studies were selected on the
basis of having memory deficits this was a domain that had
the most potential to improve.
In the current study, we saw improvements in processing
speed, which is a domain that typically exhibits significant
changes with advancing age.31,32 Among persons who are
cognitively intact, the domain of processing speed may be one
that is most malleable on account of the normative declines
that appear. Indeed, a recent cognitive training intervention
showed that gains to processing speed were the most robust
among a group of older adults, as compared to other cognitive
ability domains that were evaluated.4 Second, the length of the
intervention period used here was relatively modest, up to 60
days, whereas the work by Krikorian spanned 12 weeks29 or
up to 16 weeks.30 In some respects, the presence of statisti-
cally significant improvements in processing speed among a
cognitively healthy and highly educated sample of older adults
speaks to the robustness of these findings. Nevertheless, future
studies using NT-020 may include persons with cognitive
impairment and may also extend the intervention period.
The results of the analysis of adverse events and com-
pliance to pill counts indicated that the study was well tol-
erated by the older adult participants. Dietary interventions,
such as the one described here, were recently highlighted as
a ‘‘new opportunity’’ for clinical interventions designed to
address cognitive decline in old age.33 Indeed, the work
described here demonstrated modest improvements in one
domain of cognitive performance among a high-functioning
group of older adults.
Although the results of the current study are informative,
there are several limitations to note. First, the participants
examined here were very high functioning in terms of their
overall level of cognitive performance as well as health and
educational attainment. Had we included persons who were
less healthy cognitively or those with identifiable cognitive
impairments, we may have observed more robust findings.
Second, the 2-month follow-up period may have been too
short to observe widespread benefits to cognitive perfor-
mance. Future studies should lengthen the intervention period
to evaluate the optimal time of intervention so that maximal
results can be observed. The decision upon which this optimal
time of intervention is based may be understood by examining
the biological markers of oxidative stress and inflammation to
determine how and when they change across the intervention
period. Similarly, we are unable to draw conclusions regard-
ing the mechanism of action for the effects that we have
observed. In the future, having markers of oxidative stress and
inflammation, as well as brain-based measures of functioning,
may allow us to identify the manner by which this compound,
as well as others, may influence functioning.
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